(Reuters) - Swiss drugmaker Roche has agreed to buy privately-held U.S. diagnostics company IQuum in a deal worth up to $450 million to strengthen its molecular diagnostics business.
The Basel-based firm said it will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones.
Help employers find you! Check out all the jobs and post your resume.
